Community specific data reports for vaccine administration results, updated weekly, and data from the Public Health (DPH) COVID Community Impact Survey to help target approaches.

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season. This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age). CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here. • Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors. • These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US) • Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*. • People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

Access available resources below such as data reports, and Public Health Council presentations.

According to a forecast as of March, BioNTech's and Pfizer's vaccine against COVID-19 could generate sales revenues of nearly 22 billion U.S. dollars during 2021. The BioNTech/Pfizer vaccine was the first COVID-19 vaccine to be widely approved and used. German biotech company BioNTech saw a 156 percent growth in its shares in the last 12 months as of March 2021.

Will Moderna be the big winner? Moderna is expected to be the company with the largest sales revenues from a COVID-19 vaccine. Forecasts predict that the company will make around 43 billion U.S. dollars in sales through its vaccine. Interestingly, Moderna was established in 2010 and had never made profit before the pandemic. Thus, the development of the covid vaccine based on the latest mRNA technology will mark a definitive breakthrough for the Massachusetts-based biotech company. Moderna received significant funding through taxpayer money as well as help in research and development from the National Institutes of Health.

Vaccine pricing in a pandemic Drug pricing is always a big issue and this was also the case with COVID-19 vaccines. While some companies, like AstraZeneca, stated early on that prices for the vaccine will be on a non-profit base at least as long as the pandemic is ongoing, others took a more profit-oriented approach. However, even these companies state that their current prices are low special prices, taking into account urgent public health interests, which normally would be much higher. According to several projections, COVID-19 drugs and vaccines could establish a market worth some 40 billion U.S. dollars annually.

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data was reported at 77.600 % in 11 Apr 2022. This records an increase from the previous number of 73.900 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data is updated weekly, averaging 72.700 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 77.600 % in 11 Apr 2022 and a record low of 65.500 % in 03 Jan 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S039: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

This open dataset shows data on Cambridge residents who have received a COVID-19 vaccine at any location (e.g., mass vaccination site, pharmacy, doctor's office). These data come from the Massachusetts Department of Public Health's weekly report on vaccine doses administered by municipality. The report is released on Thursdays.
The Moderna and Pfizer vaccines require two doses administered at least 28 days apart in order to be fully vaccinated. The J&J (Janssen) vaccine requires a single dose in order to be fully vaccinated.
The category "Residents Who Received at Least One Dose" reflects the total number of individuals in the fully and partially vaccinated categories. That is, this category comprises individuals who have received one or both doses of the Moderna/Pfizer vaccine or have received the single dose J&J (Janssen) vaccine.
The category "Fully Vaccinated Residents" comprises individuals who have received both doses of the Moderna/ Pfizer vaccine or the single-dose J&J vaccine.
The category "Partially Vaccinated Residents" comprises individuals who have received only the first dose of the Moderna/Pfizer vaccine.
Source: Weekly COVID-19 Municipality Vaccination Report. Massachusetts releases updated data each Thursday at 5 p.m.

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

BackgroundThe Latin American and Caribbean (LAC) region has been one of the regions most affected by the COVID-19 pandemic, with countries presenting some of the highest numbers of cases and deaths from this disease in the world. Despite this, vaccination intention is not homogeneous in the region, and no study has evaluated the influence of the mass media on vaccination intention. The objective of this study was to evaluate the association between the use of mass media to learn about COVID-19 and the non-intention of vaccination against COVID-19 in LAC countries.MethodsAn analysis of secondary data from a Massachusetts Institute of Technology (MIT) survey was conducted in collaboration with Facebook on people's beliefs, behaviors, and norms regarding COVID-19. Crude and adjusted prevalence ratios (aPR) with their respective 95% confidence intervals (95%CI) were calculated to evaluate the association between the use of mass media and non-vaccination intention using generalized linear models of the Poisson family with logarithmic link.ResultsA total of 350,322 Facebook users over the age of 18 from LAC countries were included. 50.0% were men, 28.4% were between 18 and 30 years old, 41.4% had a high school education level, 86.1% lived in the city and 34.4% reported good health condition. The prevalence of using the mass media to learn about COVID-19 was mostly through mixed media (65.8%). The non-intention of vaccination was 10.8%. A higher prevalence of not intending to be vaccinated against COVID-19 was found in those who used traditional media (aPR = 1.36; 95%CI: 1.29–1.44; p < 0.001) and digital media (aPR = 1.70; 95%CI: 1.24–2.33; p = 0.003) compared to those using mixed media.ConclusionWe found an association between the type of mass media used to learn about COVID-19 and the non-intention of vaccination. The use of only traditional or digital information sources were associated with a higher probability of non-intention to vaccinate compared to the use of both sources.

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data was reported at 13.200 % in 11 Apr 2022. This records a decrease from the previous number of 14.100 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data is updated weekly, averaging 14.050 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 19.100 % in 14 Mar 2022 and a record low of 9.000 % in 22 Nov 2021. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S039: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

The Executive Order is relative to rescinding mandatory employee COVID vaccine or weekly testing. More information: Visit the City Manager's webpage to learn more about the current City Manager and their goals, programs, and initiatives.Informing Worcester is the City of Worcester's open data portal where interested parties can obtain public information at no cost.

United States SB: MA: COVID Test/Vaccine: Negative COVID Test: No data was reported at 80.500 % in 11 Apr 2022. This records a decrease from the previous number of 80.700 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Negative COVID Test: No data is updated weekly, averaging 76.450 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 82.800 % in 15 Nov 2021 and a record low of 66.100 % in 10 Jan 2022. United States SB: MA: COVID Test/Vaccine: Negative COVID Test: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S038: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

This archived public use dataset has 11 data elements reflecting United States COVID-19 community levels for all available counties.

The COVID-19 community levels were developed using a combination of three metrics — new COVID-19 admissions per 100,000 population in the past 7 days, the percent of staffed inpatient beds occupied by COVID-19 patients, and total new COVID-19 cases per 100,000 population in the past 7 days. The COVID-19 community level was determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days. New COVID-19 admissions and the percent of staffed inpatient beds occupied represent the current potential for strain on the health system. Data on new cases acts as an early warning indicator of potential increases in health system strain in the event of a COVID-19 surge.

Using these data, the COVID-19 community level was classified as low, medium, or high.

COVID-19 Community Levels were used to help communities and individuals make decisions based on their local context and their unique needs. Community vaccination coverage and other local information, like early alerts from surveillance, such as through wastewater or the number of emergency department visits for COVID-19, when available, can also inform decision making for health officials and individuals.

For the most accurate and up-to-date data for any county or state, visit the relevant health department website. COVID Data Tracker may display data that differ from state and local websites. This can be due to differences in how data were collected, how metrics were calculated, or the timing of web updates.

Archived Data Notes:

This dataset was renamed from "United States COVID-19 Community Levels by County as Originally Posted" to "United States COVID-19 Community Levels by County" on March 31, 2022.

March 31, 2022: Column name for county population was changed to “county_population”. No change was made to the data points previous released.

March 31, 2022: New column, “health_service_area_population”, was added to the dataset to denote the total population in the designated Health Service Area based on 2019 Census estimate.

March 31, 2022: FIPS codes for territories American Samoa, Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands were re-formatted to 5-digit numeric for records released on 3/3/2022 to be consistent with other records in the dataset.

March 31, 2022: Changes were made to the text fields in variables “county”, “state”, and “health_service_area” so the formats are consistent across releases.

March 31, 2022: The “%” sign was removed from the text field in column “covid_inpatient_bed_utilization”. No change was made to the data. As indicated in the column description, values in this column represent the percentage of staffed inpatient beds occupied by COVID-19 patients (7-day average).

March 31, 2022: Data values for columns, “county_population”, “health_service_area_number”, and “health_service_area” were backfilled for records released on 2/24/2022. These columns were added since the week of 3/3/2022, thus the values were previously missing for records released the week prior.

April 7, 2022: Updates made to data released on 3/24/2022 for Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands to correct a data mapping error.

April 21, 2022: COVID-19 Community Level (CCL) data released for counties in Nebraska for the week of April 21, 2022 have 3 counties identified in the high category and 37 in the medium category. CDC has been working with state officials to verify the data submitted, as other data systems are not providing alerts for substantial increases in disease transmission or severity in the state.

May 26, 2022: COVID-19 Community Level (CCL) data released for McCracken County, KY for the week of May 5, 2022 have been updated to correct a data processing error. McCracken County, KY should have appeared in the low community level category during the week of May 5, 2022. This correction is reflected in this update.

May 26, 2022: COVID-19 Community Level (CCL) data released for several Florida counties for the week of May 19th, 2022, have been corrected for a data processing error. Of note, Broward, Miami-Dade, Palm Beach Counties should have appeared in the high CCL category, and Osceola County should have appeared in the medium CCL category. These corrections are reflected in this update.

May 26, 2022: COVID-19 Community Level (CCL) data released for Orange County, New York for the week of May 26, 2022 displayed an erroneous case rate of zero and a CCL category of low due to a data source error. This county should have appeared in the medium CCL category.

June 2, 2022: COVID-19 Community Level (CCL) data released for Tolland County, CT for the week of May 26, 2022 have been updated to correct a data processing error. Tolland County, CT should have appeared in the medium community level category during the week of May 26, 2022. This correction is reflected in this update.

June 9, 2022: COVID-19 Community Level (CCL) data released for Tolland County, CT for the week of May 26, 2022 have been updated to correct a misspelling. The medium community level category for Tolland County, CT on the week of May 26, 2022 was misspelled as “meduim” in the data set. This correction is reflected in this update.

June 9, 2022: COVID-19 Community Level (CCL) data released for Mississippi counties for the week of June 9, 2022 should be interpreted with caution due to a reporting cadence change over the Memorial Day holiday that resulted in artificially inflated case rates in the state.

July 7, 2022: COVID-19 Community Level (CCL) data released for Rock County, Minnesota for the week of July 7, 2022 displayed an artificially low case rate and CCL category due to a data source error. This county should have appeared in the high CCL category.

July 14, 2022: COVID-19 Community Level (CCL) data released for Massachusetts counties for the week of July 14, 2022 should be interpreted with caution due to a reporting cadence change that resulted in lower than expected case rates and CCL categories in the state.

July 28, 2022: COVID-19 Community Level (CCL) data released for all Montana counties for the week of July 21, 2022 had case rates of 0 due to a reporting issue. The case rates have been corrected in this update.

July 28, 2022: COVID-19 Community Level (CCL) data released for Alaska for all weeks prior to July 21, 2022 included non-resident cases. The case rates for the time series have been corrected in this update.

July 28, 2022: A laboratory in Nevada reported a backlog of historic COVID-19 cases. As a result, the 7-day case count and rate will be inflated in Clark County, NV for the week of July 28, 2022.

August 4, 2022: COVID-19 Community Level (CCL) data was updated on August 2, 2022 in error during performance testing. Data for the week of July 28, 2022 was changed during this update due to additional case and hospital data as a result of late reporting between July 28, 2022 and August 2, 2022. Since the purpose of this data set is to provide point-in-time views of COVID-19 Community Levels on Thursdays, any changes made to the data set during the August 2, 2022 update have been reverted in this update.

August 4, 2022: COVID-19 Community Level (CCL) data for the week of July 28, 2022 for 8 counties in Utah (Beaver County, Daggett County, Duchesne County, Garfield County, Iron County, Kane County, Uintah County, and Washington County) case data was missing due to data collection issues. CDC and its partners have resolved the issue and the correction is reflected in this update.

August 4, 2022: Due to a reporting cadence change, case rates for all Alabama counties will be lower than expected. As a result, the CCL levels published on August 4, 2022 should be interpreted with caution.

August 11, 2022: COVID-19 Community Level (CCL) data for the week of August 4, 2022 for South Carolina have been updated to correct a data collection error that resulted in incorrect case data. CDC and its partners have resolved the issue and the correction is reflected in this update.

August 18, 2022: COVID-19 Community Level (CCL) data for the week of August 11, 2022 for Connecticut have been updated to correct a data ingestion error that inflated the CT case rates. CDC, in collaboration with CT, has resolved the issue and the correction is reflected in this update.

August 25, 2022: A laboratory in Tennessee reported a backlog of historic COVID-19 cases. As a result, the 7-day case count and rate may be inflated in many counties and the CCLs published on August 25, 2022 should be interpreted with caution.

August 25, 2022: Due to a data source error, the 7-day case rate for St. Louis County, Missouri, is reported as zero in the COVID-19 Community Level data released on August 25, 2022. Therefore, the COVID-19 Community Level for this county should be interpreted with caution.

September 1, 2022: Due to a reporting issue, case rates for all Nebraska counties will include 6 days of data instead of 7 days in the COVID-19 Community Level (CCL) data released on September 1, 2022. Therefore, the CCLs for all Nebraska counties should be interpreted with caution.

September 8, 2022: Due to a data processing error, the case rate for Philadelphia County, Pennsylvania,

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

To profile maternal SARS-CoV-2 vaccine-induced specific antibodies and evaluate their transplacental transfer and persistence in infants at 2, 6, 9, and 12 months of age using systems serology. This study highlights the importance of timing vaccination in pregnancy to provide optimal protection to infants in their first months of life.

ViteMaDose est un outil qui permet aux français éligibles à la vaccination contre la Covid-19 de trouver rapidement et facilement un rendez-vous chez un professionnel de santé ou un centre dans son département. Ces données sont mise à jour quotidiennement à partir des données des plateformes scannées par ViteMaDose et du fichier officiel du gouvernement. A l'heure actuelle on y trouve les lieux de vaccination détectés sur les plateformes data.gouv.fr, Doctolib, Maiia, Keldoc, Ordocli et MaPharma.

Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

Moderna generated total revenues of some 3.2 billion U.S. dollars in 2024, a massive decrease compared to the years before. The drop was mainly due to the decreasing demand for its COVID-19 vaccine Spikevax. Working hard to produce the first 'blockbuster' Moderna is a clinical stage biotech company that is pioneering messenger RNA (mRNA) therapeutics and vaccines. Beside its COVID-19 vaccine, the company is yet to generate revenues from the sale of potential drugs, and this will remain the same until it successfully completes clinical development and obtains regulatory approval for one of its medicines. Like many other biotech companies, Moderna invests significant amounts of money into research and development projects, and annual costs continue to grow. One of the very first COVID-19 vaccines approved Moderna, in partnership with the National Institutes of Health (NIH) and the Coalition for Epidemic Preparedness Innovations (CEPI), was one of the very first to develop a vaccine to fight COVID-19. The vaccine codenamed mRNA-1273 – designed and manufactured in only 25 days – prevents future infections of the novel coronavirus that has caused the pandemic. The Moderna vaccine successfully went through all necessaryclinical phases, and was the second vaccine - after the Biontech/Pfizer vaccine - to be approved for widely usage already in late 2020.

This dataset represents preliminary estimates of cumulative U.S. RSV –associated disease burden estimates for the 2024-2025 season, including outpatient visits, hospitalizations, and deaths. Real-time estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed respiratory syncytial virus (RSV) infections. The data come from the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET), a surveillance platform that captures data from hospitals that serve about 8% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of RSV-associated disease burden estimates that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent RSV-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

Note: Preliminary burden estimates are not inclusive of data from all RSV-NET sites. Due to model limitations, sites with small sample sizes can impact estimates in unpredictable ways and are excluded for the benefit of model stability. CDC is working to address model limitations and include data from all sites in final burden estimates.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

（停止更新）SB：MA：新冠病毒检测/疫苗：新冠病毒检测阴性：No在04-11-2022达80.500%，相较于04-04-2022的80.700%有所下降。（停止更新）SB：MA：新冠病毒检测/疫苗：新冠病毒检测阴性：No数据按周更新，11-15-2021至04-11-2022期间平均值为76.450%，共18份观测结果。该数据的历史最高值出现于11-15-2021，达82.800%，而历史最低值则出现于01-10-2022，为66.100%。CEIC提供的（停止更新）SB：MA：新冠病毒检测/疫苗：新冠病毒检测阴性：No数据处于定期更新的状态，数据来源于U.S. Census Bureau，数据归类于全球数据库的美国 – Table US.S039: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued)。

IntroductionCurrent SARS-CoV-2 strains continue to mutate and attempt to evade the antibody response elicited by previous exposures and vaccinations. In September of 2022, the first updated SARS-CoV-2 vaccines, designed to create immune responses specific for the variants circulating in 2022, were approved. These new vaccines, known commonly as the bivalent boost(er), include mRNA that encodes both the original Wuhan-Hu-1 spike protein as well as the spike protein specific to the Omicron BA.4 and BA.5 variants.MethodsWe recruited volunteers from University of Massachusetts student, faculty and staff members to provide samples of blood and saliva at four different time points, including pre-boost and three times post boost and analyzed samples for antibody production as well as neutralization of virus.ResultsOur data provide a comprehensive analysis of the antibody response following a single dose of the bivalent boost over a 6-month period and support previous findings that the response induced after the bivalent boost does not create a strong BA.4/BA.5-specific antibody response.ConclusionWe found no evidence of a specific anti-BA.4/BA.5 response developing over time, including in a sub-population of individuals who become infected after a single dose of the bivalent booster. Additionally, we present data that support the use of saliva samples as a reliable alternative to blood for antibody detection against specific SARS-CoV-2 antigens.